Results 101 to 110 of about 12,173,986 (325)
Conferencias anatomoclinicas: caso No. veintiuno
M. del C. A. 40 años. Ciudad de origen: Zipaquirá. Procedencia Bogotá. Servicio del Profesor Rico. NOTA CLINICA: La paciente ingresa por primera vez al Hospital el 8 de octubre de 1951, por presentar episodios psicomotores diagnosticados inicialmente ...
San Juan de Dios Hospital
doaj
A Clinical Lecture on the Rhinoplastic Operation: Delivered in the Meath Hospital and Co. Dublin Infirmary [PDF]
William Stokes
openalex +1 more source
Barnes Hospital Bulletin [PDF]
https://digitalcommons.wustl.edu/bjc_barnes_bulletin/1093/thumbnail ...
core +1 more source
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira +14 more
wiley +1 more source
Conferencias anatomoclínicas: caso no. veintisiete
Se hace una revisión de un caso clínico presentado en el Hospital San Juan de Dios, Bogotá.
San Juan de Dios Hospital
doaj
Primary and Secondary Carcinoma of the Ovary: A Statistical Record from the Pathological Institute of the London Hospital [PDF]
Gordon Ley
openalex +1 more source
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian +10 more
wiley +1 more source
Conferencias anatomoclínicas: caso no. veinticinco
Se hace una revisión de un caso clínico presentado en el Hospital San Juan de Dios, Bogotá.
San Juan de Dios Hospital
doaj
A Lecture on Small-Bore Rifle Bullet Wounds and the "Humanity" of the Present War: Delivered at St. George's Hospital, on May 1st, 1900 [PDF]
C. T. Dent
openalex +1 more source
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga +8 more
wiley +1 more source

